林业发展局终止了tirzepatide的短缺,下令在60天至90天内停止非品牌的销售。 FDA ends tirzepatide shortage, ordering off-brand sales halted within 60 to 90 days.

林业发展局宣布结束Tirzepatide的短缺,Tirzepatide是Eli Lilly体重减退和糖尿病药物Mounjaro和Zepbound的活性成分。 The FDA has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly's weight loss and diabetes drugs Mounjaro and Zepbound. 该决定要求复合药房在60至90天内停止出售非品牌版本。 This decision requires compounding pharmacies to stop selling off-brand versions within 60 to 90 days. 美国食品和药物管理局的裁决现在允许药剂师在2月18日之前分发他们的复合物供应, 大量生产商则在3月19日之前. Initially disputed, the FDA's ruling now allows pharmacists until February 18 to distribute their compounded supplies, with bulk producers having until March 19.